DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Total Non-current Assets
All assets not expected to be converted to cash within one year.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 49.1% from a year ago
Total non-current assets stood at $717K at the end of Q1 FY2026, down 49.1% from a year earlier and down 3.4% from the prior quarter. Over 3 fiscal years it compounded at +9.8% a year.
Context
- Total non-current assets amounted to 1.4% of total assets at the end of Q1 FY2026, down 2.3 pp from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -49.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 742K USD
- Year-over-year change
- -57.2%
- 4-year CAGR
- +60.4%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 742K | -57.2% |
| FY2024 | 2024-12-31 | 1.74M | +257.7% |
| FY2023 | 2023-12-31 | 485K | -13.4% |
| FY2022 | 2022-12-31 | 560K | +400.0% |
| FY2021 | 2021-12-31 | 112K | — |
Total Non-current Assets vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 total non-current assets of $717K is the lowest of the 7 companies compared; the peer median is $48.91M.
- Its year-over-year change of -49.1% is the 6th highest of 7, against a peer median of +22.6%.
- Total non-current assets amounts to 1.4% of total assets for DMAC, versus a peer median of 14.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $404.03M | +74.5% | +40.6% | 34.9% | |
| Mar 2026 | $119.04M | +11.9% | +3.9% | 32.8% | |
| Mar 2026 | $57.88M | +24.7% | +60.5% | 19.8% | |
| Mar 2026 | $39.93M | +20.5% | +2.7% | 9.5% | |
BIOABioAge Labs, Inc. | Mar 2026 | $5.79M | -69.6% | +172.8% | 1.5% |
| Mar 2026 | $861K | +43.3% | +0.0% | 1.3% | |
| Mar 2026 | $717K | -49.1% | +9.8% | 1.4% | |
| Peer median (excluding DMAC) | $48.91M | +22.6% | +22.2% | 14.6% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.